News
22h
Best Life on MSNPeople Are Complaining About Ozempic and Wegovy’s “Life-Ruining” Side EffectDebilitating headaches are reducing their quality of life, but doctors say taking these steps can help.
Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...
17h
ZME Science on MSNOzempic Is Changing More Than Waistlines as Scientists Wise Up to Concerning Side EffectsAnimal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...
19h
Onlymyhealth on MSNDoes Ozempic cause intimacy issues? ExpertOzempic a drug touted as a magical driving force for weight loss may be negatively affecting intimacy between couples ...
21h
Barchart on MSNWeightWatchers Has Exited Bankruptcy. How Should You Play WW Stock Here?Among them, WW International (WW), formerly known as WeightWatchers, hit a rough patch earlier this year, resulting in WW ...
The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...
Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.
14h
Health and Me on MSNOzempic Users Say Sex Feels ‘Repulsive’ Now— What Is The New Side Effect Of Weight Loss Drug?A section of the Ozempic users are reporting a sharp drop—or surge—in libido, with experts exploring how GLP-1 medications impact hormones, brain chemistry, and emotional well-being in unexpected ways ...
20h
Zacks.com on MSNCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...
A weight-loss doctor is warning patients not to rely on Wegovy as a cure for obesity, saying the newly available medication could be more harmful than helpful.
Terns' late-stage assets target CML & obesity with key data in Q4 2025. Explore their potential in massive markets. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results